Experimental drug plus radiation shows promise for recurrent gynecologic cancers
NCT ID NCT03968406
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing the drug talazoparib together with radiation therapy in 24 women whose gynecologic cancer (ovarian, endometrial, cervical, or related cancers) has come back after previous treatment. Talazoparib blocks enzymes that cancer cells need to grow, and radiation uses high-energy X-rays to kill cancer cells. The main goal is to find the safest dose and see if the combination can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Talazoparib (a PARP inhibitor drug) combined with radiation therapy
- What this could lead to
- If it works, this could lead to a new treatment option for women whose gynecologic cancer has returned after prior therapy.
- What could go wrong
- This is a very early Phase 1 trial with only 24 participants, so the main goal is safety, not proof of effectiveness. The combination may cause significant side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University/Sidney Kimmel Cancer Center
RECRUITINGBaltimore, Maryland, 21287, United States
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Facing the fear: a new program aims to ease anxiety in advanced cancer
- Digital therapy aims to tame the fear that haunts cancer survivors
- Can a rapid lab test guide treatment for rare gynecologic cancers?
- Targeted pill aims to halt recurrent ovarian and endometrial cancers
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers